A Phase I/II Study of Arsenic Trioxide/Bortezomib/Ascorbic Acid Combination Therapy for the Treatment of Relapsed or Refractory Multiple MyelomaJames R. Berenson, Howard Yeh, Jeffrey Matous et al.|Clinical Cancer Research|2007Cited by 123
Efficacy and safety of melphalan, arsenic trioxide and ascorbic acid combination therapy in patients with relapsed or refractory multiple myeloma: a prospective, multicentre, phase II, single‐arm studyJames R. Berenson, Regina A. Swift, Alberto Bessudo et al.|British Journal of Haematology|2006Cited by 83
Serum pleiotrophin levels are elevated in multiple myeloma patients and correlate with disease statusHoward Yeh, James R. Berenson, Haiming Chen et al.|British Journal of Haematology|2006Cited by 16
A Phase I/II Trial Evaluating the Combination of Arsenic Trioxide, Bortezomib and Ascorbic Acid for Patients with Relapsed or Refractory Multiple Myeloma.James R. Berenson, Sal Bevivino, J. Matouš et al.|Blood|2005Cited by 11